Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes

University of Michigan Rogel Cancer Center · NCT06927947

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
625
US sites recruiting
1
Study start
September 23, 2025
Record last updated
June 15, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.

Being studied: Communication Intervention; Health Promotion and Education; Informational Intervention; Survey Administration

Conditions: Hereditary Malignant Neoplasm; Hereditary Neoplastic Syndrome

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome
  • PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic
  • PROBANDS: ≥ 18 years old
  • PROBANDS: Able to speak and read English
  • PROBANDS: Access to the internet
  • RELATIVES: Biological relative of proband
  • RELATIVES: ≥ 18 years old
  • RELATIVES: Able to speak and read English
  • RELATIVES: Access to the internet
  • RELATIVES: Have not completed germline genetic testing, per self-report at baseline

Exclusion Criteria

  • RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline

Recruiting US locations

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, MI 48109

    Site contact: MiGHT HelpLine · 734-764-4044 · MiGHT-Cascade@med.umich.edu

Study contacts (from the official record)

  • MiGHT HelpLine · (734) 764-4044 · MiGHT-Cascade@med.umich.edu
All healthy volunteers studies in Michigan →
Navigation Interventions to Improve Cascade Genetic Testing Among… (NCT06927947) | Bored Studies